EUCTR2011-003065-15-FI进行中（未招募）1 期
PRINCIPAL: A Prospective Observational Study of Real World Treatment Patterns and Treatment Outcomes in Patients with Advanced or Metastatic Renal Cell Carcinoma Receiving Pazopanib - PRINCIPA
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 700
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion Criteria
- •Specific information regarding warnings, precautions, contraindications, adverse events,
- •and other pertinent information regarding pazopanib that may impact patient treatment is
- •found in the local product labeling.
- •Deviations from inclusion criteria are not allowed because they can potentially jeopardize
- •the scientific integrity of the study. Therefore, adherence to the criteria as specified in the
- •protocol is essential.
- •Patients eligible for enrolment in the study must meet all of the following criteria:
- •Age = 18 years at enrollment
- •Documented diagnosis of advanced and/or metastatic clear cell or predominantly
- •clear cell RCC
- •Clinical decision made to initiate treatment with pazopanib prior to enrollment in the
- •study, but within 30 days of enrollment
- •Willing and able to provide written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 600
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •Exclusion Criteria
- •Deviations from exclusion criteria are not allowed because they can potentially
- •jeopardize the scientific integrity of the study. Therefore, adherence to the criteria as
- •specified in the protocol is essential.
- •Patients meeting any of the following criteria must not be enrolled in the study:
- •Patients currently participating in any interventional clinical trials in which treatment
- •regimen and/or monitoring is dictated by a protocol
- •Previous exposure to an investigational or licensed multi-kinase inhibitor or an anti-
- •VEGF angiogenesis inhibitor for advanced or metastatic disease (for guidance, refer
- •to Appendix 1 located in the protocol).
- •Life expectancy < 12 weeks
研究者
相似试验
已完成
不适用
An observational multicenter study to assess the risk factor profile of early Coronary Artery Disease (CAD) in IndiansCTRI/2012/12/003232otus Clinical Research Academy2,000
已完成
不适用
Prospective, Systematic Observational Study on the Daily Use of Cilostazol (Pletal®) in Clinical Vascular Surgical Practice – Significant Improvement of Walking Distance and Quality of Life for Patients with PAOD, Stage II bI70.22DRKS00011235niversitätsklinik für Allgemein-, Viszeral- und Gefäßchirurgie146
终止
不适用
A Prospective Observational Study Assessing The Role of IL-6 On The Platelet Protective Effects of Paclitaxel-based Chemotherapy in Patients with Epithelial Ovarian CancerCancer - Ovarian and primary peritonealEpithelial Ovarian CancerACTRN12616000923460Icon Cancer Foundation6
招募中
不适用
A Prospective Observational study to describe the pattern and effectiveness of the utilization of different treatment options for Metastatic Renal Cell CarcinomaPatients with:-histologically confirmed metastatic renal cell cancer-treated by immunotherapy and/or TKID09.7renal cell carcinomaLBCTR2020074518General Research Grant185
进行中（未招募）
不适用
POPPY Pharmacokinetic and clinical observations in people over fiftyA prospective, observational study to examine the effects of ageing on the clinical outcomes of people living with HIV in England and Ireland.HIVMedDRA version: 14.1Level: PTClassification code 10000807Term: Acute HIV infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2012-003581-40-GBImperial College, Research Governance Manager2,000